DescriptionKlogene Therapeutics is a Boston-based pre-clinical stage gene therapy startup company developing novel treatments for neurodegenerative diseases. The company’s therapeutic strategy is based on increasing the level of Klotho protein in the brain, using adeno-associated virus vectors (AAV) as the delivery mechanism for the Klotho gene. Kogenix has obtained an exclusive license to intellectual property, covered in a recent patent application, from an academic institution.
Our scientific founders have deep expertise and over 80 years of combined experience in neuroscience and gene therapy. Kogenix, headquartered in Boston, has strong scientific ties and collaborations with Universitat Autonoma de Barcelona and its gene therapy viral vector production unit, as well as the Boston University School of Medicine. Our pre-clinical programs include: (i) a neuroprotective Klotho gene therapy for Alzheimer’s disease and (ii) a re-myelination inducing Klotho gene therapy for Multiple Sclerosis.